KAZIA THERAPEUTICS LIMITED (KZIA) at GUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - KAZIA THERAPEUTICS LTD

Based on the transcript provided, here is the summary of forward-looking statements for Kaseya Therapeutics:

• Explicit Guidance:

  • Cash Runway: Management has "little over $80 million" in cash with a runway extending "well into 2031" following recent financing.
  • Enrollment Timelines:
    • Anticipates enrolling all 36 patients in the Phase 1B Stage 4 Triple Negative Breast Cancer (TNBC) trial "by next summer" (2027).
    • Expects full enrollment of ~78 patients in the HR+ HER2- extension trial "by the end of 2027."
    • Projects enrollment of ~90 patients in the Phase 2 Colorectal Cancer (CRC) trial "by the end of next year" (2027).
  • Data Milestones:
    • Plans to provide "meaningful updates" (e.g., 10–12 page data readouts) during 2027, including "healthy updates" throughout the year for TNBC, HR+, and CRC.
    • Targets clinical initiation for the early-stage TNBC (Stage II/III) trial in the "second half of 2027."
    • Expects to be "in the clinic" (IND/enabling and clinical) with the PDA1 protein degrader asset "before the end of the year, 2027."
    • Scheduled updates for the DB1 chromatin-focused protein degrader platform in "early 2027," potentially leading to a dedicated R&D day.

• Business-Segment Outlook:

  • TNBC (Stage 4): Ongoing Phase 1B trial (Paxalisib + Pembrolizumab + Chemo) targets 36 patients; early data in first 6 patients showed 1 complete metabolic response and 4 partial responses. Protocol amended to include patients with CPS scores 1–10 (previously ineligible for Pembro).
  • TNBC (Early Stage): Launching adjuvant trials for Stage II/III high-risk patients with residual disease; initiation expected in H2 2027 to address recurrence.
  • HR+ / HER2-: Initiating an extension of the ongoing trial (Combination: Paxalisib + Fulvestrant + CDK4-6) in the second-line setting; first patient enrollment expected "by the end of this year" (2024) with two dose levels (15mg and 30mg).
  • Colorectal Cancer (CRC): Launching Phase 2 study in Q1 2027 focusing on dMMR/MSS (PMMR) CRC (80–85% of metastatic CRC). Study design includes Paxalisib monotherapy (15mg/30mg) and combo with Pembrolizumab in a third-line setting with a comparator arm.
  • Pipeline Assets:
    • EVT801: Secondary asset (VEGFR3 specific); Phase 1 completed.
    • Protein Degraders: Two platforms (DB1 chromatin-focused, PDA1/PD-1 degrader). The PDA1 lead asset (NDL2) targets nuclear-based PD-L1 and is expected to enter clinical trials by end of 2027.

• Market and Competitive Outlook:

  • Differentiation Strategy: Explicitly aims to avoid being a "fast follower" or "me too" drug in the PI3K/mTOR space; differentiates via unique ability to cross the nuclear membrane to target non-canonical epigenetic pathways and reprogram cancer stem cells/CD8 T-cells.
  • Market Gaps: Targeting unmet needs in patients ineligible for standard checkpoint inhibitors (PD-L1 low/negative) and the high-recurrence population in early-stage TNBC.
  • Competitive Landscape: Notes that checkpoint inhibitors have historically failed in PMMR colorectal cancer (80–85% of metastatic cases) and that few other PI3K inhibitors are currently active in this specific CRC setting.
  • Pricing/Dosing: Utilizes "much lower doses" daily to minimize on-target toxicities (hyperglycemia, stomatitis) compared to historical PI3K/mTOR profiles.

• Macro / Industry Outlook:

  • Clinical Development: Management frames 2026 as a period of "execution around capital markets" and 2027 as a definitive "year of execution" for clinical development and data readouts.
  • Biotech Sector: Highlights the unique capital position of a micro-cap biotech with cash extending to 2031, allowing for full execution of the pipeline without near-term financing dilution risks.

• Strategic Initiatives:

  • Trial Expansion: Expanding indications from neuro-oncology origins to TNBC, HR+, and CRC based on preclinical "epigenetic reprogramming" data.
  • R&D Day: Scheduled for December 2nd to present preclinical data on protein degraders and benchmarking studies.
  • Investment Focus: Continued investment in translational research to demonstrate "downstream epigenetic effects" and benchmark against traditional PI3K inhibitors.

• Risks and Headwinds to Outlook:

  • Regulatory/Approval: No specific FDA approval dates given; outlook relies on successful completion of enrollment and positive data readouts in 2027.
  • Data Readout Timing: Future updates (PFS/OS) for HR+ and CRC are expected to be "later readouts," necessitating reliance on early translational biomarker data for near-term conviction.
  • Toxicity Assumption: The guidance relies on the hypothesis that lower doses will avoid "on-target effects" (mucositis, hyperglycemia); failure to maintain this safety profile could alter trial design or feasibility.
  • Unproven Mechanism: The "epigenetic reprogramming" effect in humans is still being validated beyond the initial 6 TNBC patients; if not confirmed, the differentiation strategy collapses.

• Management Tone on the Future:

  • Confidence: High confidence in the "novelty" of the mechanism and the "unique space" of the company's capital position.
  • Certainty: Uses definitive language regarding enrollment timelines ("expect to have all of those patients enrolled," "first patient enrolled by end of this year").
  • Forward-Looking: Describes 2027 as the critical year for validating the unique mechanism and achieving commercial potential in early-stage TNBC.
  • Hedges: Uses standard scientific caution ("hypothesis," "preclinically wise," "looking to show") when discussing the translation of epigenetic effects to patient survival outcomes.

• Miscellaneous:

  • Mechanism of Action (MOA): Paxalisib is a small, lipophilic molecule capable of crossing the blood-brain barrier and the nuclear membrane, allowing it to impact a "non-canonical pathway" in the nucleus that traditional PI3K/mTOR inhibitors cannot reach.
  • Biomarkers: Key early readouts will focus on reductions in circulating tumor cells (CTCs) and reprogramming of terminally exhausted CD8 T-cells (functional conversion rather than cell death).